A Single-arm Study to Evaluate the Safety and Efficacy of Recombinant Oncolytic Virus M1 (M1-c6v1) Combined With Anti-PD-1 Antibody SHR-1210 and Apatinib for Treatment of Patients With Advanced / Metastatic Hepatocellular Carcinoma
Latest Information Update: 05 Jan 2023
At a glance
- Drugs Camrelizumab (Primary) ; Recombinant oncolytic virus M1-Guangzhou Virotech Pharmaceutical (Primary) ; Rivoceranib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 20 Jan 2021 Planned initiation date changed from 28 Dec 2020 to 25 Jan 2021.
- 16 Dec 2020 New trial record